HTG Molecular Diagnostics, Inc. (HTGM) Financial Statements (2024 and earlier)

Company Profile

Business Address 3430 E. GLOBAL LOOP
TUCSON, AZ 85706
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12,21121,94328,69633,03031,1149,969
Cash and cash equivalents12,2119,60022,3987,6208,4339,969
Short-term investments 12,3436,29825,41022,681 
Restricted cash and investments    3,270  
Receivables1,4222,0921,5893,1645,0136,356
Inventory, net of allowances, customer advances and progress billings9091,9881,4921,2701,3071,181
Inventory9091,9881,4921,2701,3071,181
Deferred costs    140593
Other undisclosed current assets1,1101,1631,094493509440
Total current assets:15,65127,18732,87141,36838,00117,948
Noncurrent Assets
Operating lease, right-of-use asset1,0071,3451,0091,209
Property, plant and equipment5981,1191,2272,2402,3743,305
Restricted cash and investments     3,270 
Deferred costs     593
Other noncurrent assets52180990302  
Other undisclosed noncurrent assets     67 
Total noncurrent assets:2,1263,2742,3273,7525,7703,308
TOTAL ASSETS:17,77830,46135,19845,11943,77121,256
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,3673,6722,8093,5335,2086,186
Accounts payable1,1571,6491,3491,6631,8502,439
Accrued liabilities2,2102,0231,4601,8703,3583,747
Deferred revenue  125185426
Debt3,8125,1683,0223,747 5,794
Asset retirement obligation4465485131,1521,290496
Deferred revenue and credits666
Contract with customer, liability333
Other liabilities170172341186200
Other undisclosed current liabilities475414685   
Total current liabilities:8,2719,9447,2368,8997,01713,342
Noncurrent Liabilities
Long-term debt and lease obligation  6,1598,9857,5089,6792,961
Long-term debt, excluding current maturities  5,1798,5686,8729,6792,961
Finance lease, liability  3148 
Liabilities, other than long-term debt4,1153,9894,5404,7435,9838,013
Asset retirement obligations3,5193,9014,4794,4995,7037,521
Other liabilities508860244280492
Operating lease, liability546949369636
Other undisclosed noncurrent liabilities(15)(49)(48)   
Total noncurrent liabilities:4,10010,10013,47712,25115,66210,974
Other undisclosed liabilities1517    
Total liabilities:12,38620,06120,71321,15022,67924,316
Equity
Equity, attributable to parent5,39210,40014,48523,97021,092(3,060)
Preferred stock  00   
Common stock285582914
Additional paid in capital235,314218,723205,662194,234172,087131,493
Accumulated other comprehensive income (loss)325(5)(3) 
Accumulated deficit(229,928)(208,333)(191,188)(170,318)(151,020)(134,566)
Total equity:5,39210,40014,48523,97021,092(3,060)
TOTAL LIABILITIES AND EQUITY:17,77830,46135,19845,11943,77121,256

Income Statement (P&L) ($ in thousands)

3/31/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues6,3668,9078,54919,20421,50414,760
Revenue, net14,760
Cost of revenue(4,572)(4,095)(3,992)(8,911)(5,090)(4,972)
Cost of goods and services sold(4,572)(4,095)(3,992)(8,911)(5,090)(1,609)
Gross profit:1,7944,8124,55710,29316,4139,788
Operating expenses(22,624)(22,636)(24,143)(29,253)(32,573)(27,510)
Operating loss:(20,830)(17,824)(19,586)(18,960)(16,159)(17,723)
Nonoperating income (expense)(754)701(1,270)(334)(291)(1,234)
Interest and debt expense(857)(1,065)(522)(958)(105)(1,308)
Loss from continuing operations before equity method investments, income taxes:(22,440)(18,187)(21,378)(20,252)(16,555)(20,265)
Other undisclosed income from continuing operations before income taxes8571,0655229581051,308
Loss from continuing operations before income taxes:(21,584)(17,123)(20,856)(19,294)(16,450)(18,957)
Income tax expense(11)(22)(14)(3)(4)(3)
Loss from continuing operations:(21,594)(17,145)(20,870)(19,298)(16,454)(18,960)
Loss before gain (loss) on sale of properties:(17,145)(20,870)(19,298)(16,454)(18,960)
Net loss available to common stockholders, diluted:(21,594)(17,145)(20,870)(19,298)(16,454)(18,960)

Comprehensive Income ($ in thousands)

3/31/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(21,594)(17,145)(20,870)(19,298)(16,454)(18,960)
Other comprehensive income (loss) (3)10(2)(3)1
Other undisclosed comprehensive income      
Comprehensive loss:(21,594)(17,149)(20,860)(19,299)(16,457)(18,959)
Other undisclosed comprehensive income, net of tax, attributable to parent1     
Comprehensive loss, net of tax, attributable to parent:(21,594)(17,149)(20,860)(19,299)(16,457)(18,959)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: